JP2017527600A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017527600A5 JP2017527600A5 JP2017514892A JP2017514892A JP2017527600A5 JP 2017527600 A5 JP2017527600 A5 JP 2017527600A5 JP 2017514892 A JP2017514892 A JP 2017514892A JP 2017514892 A JP2017514892 A JP 2017514892A JP 2017527600 A5 JP2017527600 A5 JP 2017527600A5
- Authority
- JP
- Japan
- Prior art keywords
- formulation
- formulation according
- pharmaceutically acceptable
- active substance
- amount
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000009472 formulation Methods 0.000 claims 29
- 239000000203 mixture Substances 0.000 claims 29
- 239000002245 particle Substances 0.000 claims 13
- 239000013543 active substance Substances 0.000 claims 9
- 150000003839 salts Chemical class 0.000 claims 8
- 239000000546 pharmaceutical excipient Substances 0.000 claims 7
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims 5
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims 5
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims 5
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims 5
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims 4
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 claims 4
- 239000004354 Hydroxyethyl cellulose Substances 0.000 claims 4
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 claims 4
- 239000007788 liquid Substances 0.000 claims 4
- 229920000642 polymer Polymers 0.000 claims 4
- 229930003448 Vitamin K Natural products 0.000 claims 3
- SHUZOJHMOBOZST-UHFFFAOYSA-N phylloquinone Natural products CC(C)CCCCC(C)CCC(C)CCCC(=CCC1=C(C)C(=O)c2ccccc2C1=O)C SHUZOJHMOBOZST-UHFFFAOYSA-N 0.000 claims 3
- 235000019168 vitamin K Nutrition 0.000 claims 3
- 239000011712 vitamin K Substances 0.000 claims 3
- 150000003721 vitamin K derivatives Chemical class 0.000 claims 3
- 229940046010 vitamin k Drugs 0.000 claims 3
- 229920002134 Carboxymethyl cellulose Polymers 0.000 claims 2
- 208000005590 Choroidal Neovascularization Diseases 0.000 claims 2
- 206010060823 Choroidal neovascularisation Diseases 0.000 claims 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 2
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 claims 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 claims 2
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 claims 2
- 239000004721 Polyphenylene oxide Substances 0.000 claims 2
- 206010064930 age-related macular degeneration Diseases 0.000 claims 2
- 125000002877 alkyl aryl group Chemical group 0.000 claims 2
- 239000001768 carboxy methyl cellulose Substances 0.000 claims 2
- 235000010948 carboxy methyl cellulose Nutrition 0.000 claims 2
- 239000008112 carboxymethyl-cellulose Substances 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 235000011187 glycerol Nutrition 0.000 claims 2
- 208000002780 macular degeneration Diseases 0.000 claims 2
- 239000002736 nonionic surfactant Substances 0.000 claims 2
- 230000001575 pathological effect Effects 0.000 claims 2
- 229920000570 polyether Polymers 0.000 claims 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims 2
- 238000001356 surgical procedure Methods 0.000 claims 2
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 claims 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 claims 2
- 229960000281 trometamol Drugs 0.000 claims 2
- 208000021089 Coats disease Diseases 0.000 claims 1
- 206010012689 Diabetic retinopathy Diseases 0.000 claims 1
- 208000010412 Glaucoma Diseases 0.000 claims 1
- 206010061260 Lacrimal cyst Diseases 0.000 claims 1
- 208000001344 Macular Edema Diseases 0.000 claims 1
- 206010025415 Macular oedema Diseases 0.000 claims 1
- 206010030113 Oedema Diseases 0.000 claims 1
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical group C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 claims 1
- 208000007135 Retinal Neovascularization Diseases 0.000 claims 1
- 208000008709 Retinal Telangiectasis Diseases 0.000 claims 1
- 206010038933 Retinopathy of prematurity Diseases 0.000 claims 1
- 206010038935 Retinopathy sickle cell Diseases 0.000 claims 1
- 206010046851 Uveitis Diseases 0.000 claims 1
- 230000033115 angiogenesis Effects 0.000 claims 1
- 208000030533 eye disease Diseases 0.000 claims 1
- 208000014674 injury Diseases 0.000 claims 1
- 208000028867 ischemia Diseases 0.000 claims 1
- 201000010230 macular retinal edema Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 201000003142 neovascular glaucoma Diseases 0.000 claims 1
- 235000005152 nicotinamide Nutrition 0.000 claims 1
- 239000011570 nicotinamide Substances 0.000 claims 1
- 229960003966 nicotinamide Drugs 0.000 claims 1
- 229960003512 nicotinic acid Drugs 0.000 claims 1
- 235000001968 nicotinic acid Nutrition 0.000 claims 1
- 239000011664 nicotinic acid Substances 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 229960000502 poloxamer Drugs 0.000 claims 1
- 229920001983 poloxamer Polymers 0.000 claims 1
- 229920000136 polysorbate Polymers 0.000 claims 1
- 229950008882 polysorbate Drugs 0.000 claims 1
- 229920000053 polysorbate 80 Polymers 0.000 claims 1
- 229940069328 povidone Drugs 0.000 claims 1
- 210000001525 retina Anatomy 0.000 claims 1
- 235000002639 sodium chloride Nutrition 0.000 claims 1
- 239000000725 suspension Substances 0.000 claims 1
- 230000000699 topical effect Effects 0.000 claims 1
- 230000008733 trauma Effects 0.000 claims 1
- MDYZKJNTKZIUSK-UHFFFAOYSA-N tyloxapol Chemical group O=C.C1CO1.CC(C)(C)CC(C)(C)C1=CC=C(O)C=C1 MDYZKJNTKZIUSK-UHFFFAOYSA-N 0.000 claims 1
- 229960004224 tyloxapol Drugs 0.000 claims 1
- 229920001664 tyloxapol Polymers 0.000 claims 1
- 210000003462 vein Anatomy 0.000 claims 1
- 0 CC(NC(NCC*CN1CCCC1)=C)=C(C(OCC1C(F)=CC(*)=CC1F)=*)C(N)=O Chemical compound CC(NC(NCC*CN1CCCC1)=C)=C(C(OCC1C(F)=CC(*)=CC1F)=*)C(N)=O 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2020016790A JP6890692B2 (ja) | 2014-09-17 | 2020-02-04 | 薬物送達および前眼部保護のための眼用製剤 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462051794P | 2014-09-17 | 2014-09-17 | |
| US62/051,794 | 2014-09-17 | ||
| PCT/US2015/050818 WO2016044671A1 (en) | 2014-09-17 | 2015-09-17 | Ocular formulations for drug-delivery and protection of the anterior segment of the eye |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020016790A Division JP6890692B2 (ja) | 2014-09-17 | 2020-02-04 | 薬物送達および前眼部保護のための眼用製剤 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017527600A JP2017527600A (ja) | 2017-09-21 |
| JP2017527600A5 true JP2017527600A5 (enExample) | 2018-10-18 |
| JP6657193B2 JP6657193B2 (ja) | 2020-03-04 |
Family
ID=55453708
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017514892A Active JP6657193B2 (ja) | 2014-09-17 | 2015-09-17 | 薬物送達および前眼部保護のための眼用製剤 |
| JP2020016790A Active JP6890692B2 (ja) | 2014-09-17 | 2020-02-04 | 薬物送達および前眼部保護のための眼用製剤 |
| JP2021086698A Active JP7176042B2 (ja) | 2014-09-17 | 2021-05-24 | 薬物送達および前眼部保護のための眼用製剤 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020016790A Active JP6890692B2 (ja) | 2014-09-17 | 2020-02-04 | 薬物送達および前眼部保護のための眼用製剤 |
| JP2021086698A Active JP7176042B2 (ja) | 2014-09-17 | 2021-05-24 | 薬物送達および前眼部保護のための眼用製剤 |
Country Status (18)
| Country | Link |
|---|---|
| US (7) | US9814702B2 (enExample) |
| EP (2) | EP3193867B1 (enExample) |
| JP (3) | JP6657193B2 (enExample) |
| KR (2) | KR102555091B1 (enExample) |
| CN (2) | CN106999476B (enExample) |
| AU (2) | AU2015317531B2 (enExample) |
| DK (1) | DK3193867T3 (enExample) |
| ES (2) | ES2863601T3 (enExample) |
| HU (1) | HUE053852T2 (enExample) |
| IL (2) | IL282504B (enExample) |
| MA (1) | MA56220A (enExample) |
| MX (2) | MX383792B (enExample) |
| NZ (1) | NZ767710A (enExample) |
| PL (1) | PL3193867T3 (enExample) |
| PT (1) | PT3193867T (enExample) |
| RU (2) | RU2704810C2 (enExample) |
| WO (1) | WO2016044671A1 (enExample) |
| ZA (1) | ZA201701303B (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2015317531B2 (en) * | 2014-09-17 | 2020-11-19 | Panoptica, Inc. | Ocular formulations for drug-delivery and protection of the anterior segment of the eye |
| EP3616723B1 (en) * | 2018-07-18 | 2024-08-07 | Wenzhou Medical University | Use of nicotinic acid or prazosin for treating myopia |
| CN113164551A (zh) * | 2018-10-24 | 2021-07-23 | 雅利斯塔制药公司 | 脂联素肽模拟物制剂 |
| AU2021322232A1 (en) * | 2020-08-05 | 2023-03-23 | TearClear Corp. | Systems and methods for preservative removal from ophthalmic formulations |
| JP2022131565A (ja) * | 2021-02-26 | 2022-09-07 | ロート製薬株式会社 | 水性医薬組成物 |
| KR102633321B1 (ko) * | 2021-05-11 | 2024-02-05 | 연세대학교 산학협력단 | 노인성 황반변성의 예방 또는 치료를 위한 약학 조성물 |
| CN115521901B (zh) * | 2022-10-12 | 2023-09-05 | 中国医学科学院医学生物学研究所 | 永生化树鼩视网膜微血管内皮细胞株及其构建方法与应用 |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2792997A (en) * | 1997-05-26 | 1998-12-30 | New Vision Co., Ltd. | Medicinal compositions for topical administration containing vitamin d and vitamin k |
| UA60365C2 (uk) | 1998-06-04 | 2003-10-15 | Пфайзер Продактс Інк. | Похідні ізотіазолу, спосіб їх одержання, фармацевтична композиція та спосіб лікування гіперпроліферативного захворювання у ссавця |
| MXPA03004714A (es) * | 2000-11-28 | 2003-08-19 | Pfizer Prod Inc | Sales de una isotiazol-4-carboxamida y su uso como agentes de antihiperproliferacion. |
| US20060127505A1 (en) * | 2002-01-16 | 2006-06-15 | David Haines | Anti-inflammatory formulations |
| US20050074497A1 (en) * | 2003-04-09 | 2005-04-07 | Schultz Clyde L. | Hydrogels used to deliver medicaments to the eye for the treatment of posterior segment diseases |
| CN1946352A (zh) * | 2004-04-09 | 2007-04-11 | 狄科特康坦特公司 | 递送药物至眼以治疗后段疾病的方法和物品 |
| US20060134226A1 (en) * | 2004-11-16 | 2006-06-22 | Todd Leonard | Compositions useful to treat ocular neovascular diseases and macular degeneration |
| WO2007041499A2 (en) * | 2005-09-30 | 2007-04-12 | Lipoprotein Technologies, Inc. | Cox inhibitor and nicotinic acid compositions and methods |
| WO2009129859A1 (en) * | 2008-04-24 | 2009-10-29 | Dr. Gerhard Mann Chem.-Pharm. Fabrik Gmbh | Compositions and methods for maintaining, strengthening, improving, or promoting eye health |
| CN105362221A (zh) * | 2009-03-03 | 2016-03-02 | 爱尔康研究有限公司 | 向眼部递送受体酪氨酸激酶抑制性(RTKi)化合物的药物组合物 |
| WO2011019678A1 (en) * | 2009-08-11 | 2011-02-17 | Allergan, Inc. | Isothiozoles for treating conditions of the eye |
| KR20120100964A (ko) * | 2009-09-30 | 2012-09-12 | 바이타패스 제네틱스 인코포레이티드 | 개인용 보조인자 및 사용 방법 |
| JP2013531067A (ja) * | 2010-07-19 | 2013-08-01 | バイエル ヘルスケア リミティド ライアビリティ カンパニー | 疾病及び状態の処置及び予防のためのフルオロ置換オメガ−カルボキシアリールジフェニル尿素を用いた組み合わせ薬 |
| JP5956992B2 (ja) * | 2010-08-17 | 2016-07-27 | オーエイチアール・ファーマシューティカル・インコーポレイテッドＯｈｒ Ｐｈａｒｍａｃｅｕｔｉｃａｌ，Ｉｎｃ． | スクアラミンの眼用製剤 |
| EP2444063A1 (en) * | 2010-10-20 | 2012-04-25 | Novaliq GmbH | Liquid pharmaceutical compositions for the delivery of active ingredients |
| US20110052678A1 (en) * | 2010-11-05 | 2011-03-03 | Shantha Totada R | Method for treating age related macular degeneration |
| US20140161720A1 (en) * | 2011-05-26 | 2014-06-12 | The General Hospital Corporation | Treatment of angiogenic- or vascular-associated diseases |
| JP6363506B2 (ja) * | 2011-11-15 | 2018-07-25 | アラーガン、インコーポレイテッドＡｌｌｅｒｇａｎ，Ｉｎｃｏｒｐｏｒａｔｅｄ | シクロスポリンａ２型の懸濁剤 |
| HK1205461A1 (zh) * | 2012-02-22 | 2015-12-18 | Trustees Of Tufts College | 用於眼部传输治疗剂的组合物和方法 |
| KR102433489B1 (ko) | 2013-03-14 | 2022-08-17 | 팬옵티카, 인크. | 눈의 후안부로의 약물 전달을 위한 안구용 제제 |
| AU2015317531B2 (en) * | 2014-09-17 | 2020-11-19 | Panoptica, Inc. | Ocular formulations for drug-delivery and protection of the anterior segment of the eye |
-
2015
- 2015-09-17 AU AU2015317531A patent/AU2015317531B2/en active Active
- 2015-09-17 MX MX2017003436A patent/MX383792B/es unknown
- 2015-09-17 KR KR1020227033489A patent/KR102555091B1/ko active Active
- 2015-09-17 DK DK15841620.6T patent/DK3193867T3/da active
- 2015-09-17 PL PL15841620T patent/PL3193867T3/pl unknown
- 2015-09-17 NZ NZ767710A patent/NZ767710A/en unknown
- 2015-09-17 CN CN201580049902.7A patent/CN106999476B/zh active Active
- 2015-09-17 RU RU2017112930A patent/RU2704810C2/ru active
- 2015-09-17 WO PCT/US2015/050818 patent/WO2016044671A1/en not_active Ceased
- 2015-09-17 CN CN202110452774.8A patent/CN113209000B/zh active Active
- 2015-09-17 PT PT158416206T patent/PT3193867T/pt unknown
- 2015-09-17 RU RU2019132429A patent/RU2768652C1/ru active
- 2015-09-17 KR KR1020177010289A patent/KR102450020B1/ko active Active
- 2015-09-17 EP EP15841620.6A patent/EP3193867B1/en active Active
- 2015-09-17 HU HUE15841620A patent/HUE053852T2/hu unknown
- 2015-09-17 MA MA056220A patent/MA56220A/fr unknown
- 2015-09-17 JP JP2017514892A patent/JP6657193B2/ja active Active
- 2015-09-17 EP EP21151865.9A patent/EP3878449B1/en active Active
- 2015-09-17 ES ES15841620T patent/ES2863601T3/es active Active
- 2015-09-17 US US14/857,758 patent/US9814702B2/en active Active
- 2015-09-17 IL IL282504A patent/IL282504B/en unknown
- 2015-09-17 ES ES21151865T patent/ES3010497T3/es active Active
-
2016
- 2016-03-25 US US15/080,893 patent/US9623011B2/en active Active
-
2017
- 2017-02-21 ZA ZA2017/01303A patent/ZA201701303B/en unknown
- 2017-03-08 IL IL251019A patent/IL251019B/en active IP Right Grant
- 2017-03-15 MX MX2021006070A patent/MX2021006070A/es unknown
- 2017-09-28 US US15/718,176 patent/US10183014B2/en active Active
-
2018
- 2018-11-13 US US16/189,019 patent/US20190314343A1/en not_active Abandoned
-
2020
- 2020-02-04 JP JP2020016790A patent/JP6890692B2/ja active Active
- 2020-10-13 US US17/068,954 patent/US20210275501A1/en not_active Abandoned
-
2021
- 2021-02-16 AU AU2021200997A patent/AU2021200997B2/en active Active
- 2021-05-24 JP JP2021086698A patent/JP7176042B2/ja active Active
-
2023
- 2023-11-02 US US18/500,416 patent/US20240277674A1/en not_active Abandoned
-
2025
- 2025-02-25 US US19/062,440 patent/US20260048039A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Schopf et al. | Topical ocular drug delivery to the back of the eye by mucus-penetrating particles | |
| JP6629840B2 (ja) | 眼の疾患および障害を処置するための化合物 | |
| KR102525438B1 (ko) | 안과용 활성 약학 성분 전달을 위한 고형 사이클로덱스트린 복합체의 제조 | |
| JP7569336B2 (ja) | マイクロエマルション組成物 | |
| RU2018128980A (ru) | Офтальмологические составы для доставки лекарственных средств к заднему сегменту глаза | |
| US20020035264A1 (en) | Ophthalmic formulation of a selective cyclooxygenase-2 inhibitory drug | |
| JP7716996B2 (ja) | 薬剤を含む水性組成物のｐＨを安定化させるための方法 | |
| RU2017112930A (ru) | Офтальмологические составы для доставки лекарств и защиты переднего отдела глаза | |
| JP2017505822A5 (enExample) | ||
| JP2010536797A5 (enExample) | ||
| CN107735091B (zh) | 包含伊马替尼作为活性成分的用于预防和治疗干眼病的药物组合物 | |
| CN114786480A (zh) | 使用内皮素受体拮抗剂治疗眼部疾病 | |
| JP2024516929A5 (enExample) | ||
| JP2019534269A5 (enExample) | ||
| KR20220139901A (ko) | 사전 활성화된 티오머를 기반으로 하는 점막 접착성 고체 또는 반고체 안과용 전달 시스템 | |
| JP2021138710A5 (enExample) | ||
| TW201705956A (zh) | 唑系抗真菌藥之對眼瞼皮膚的投與 | |
| CN110022856B (zh) | 用于降低眼压的眼用组合物 | |
| US20210177751A1 (en) | Hypotonic hydrogel formulations for enhanced transport of active agents at mucosal surfaces | |
| CN104721145A (zh) | 一种布佐林胺纳米粒眼用制剂及其制备方法 | |
| JP2025511845A5 (enExample) | ||
| WO2006118170A1 (ja) | 角膜疾患治療剤 | |
| RU2022106937A (ru) | Офтальмологические составы для доставки лекарств и защиты переднего отдела глаза | |
| McCann | Advances and challenges in topical ocular medications | |
| HK40005358B (en) | Eye-drop composition for lowering intraocular pressure |